(Reuters) -British consumer healthcare group Haleon reported third-quarter organic revenue growth marginally above market estimates on Thursday, helped by strong demand for its oral health products.
Slowing consumer spending in the U.S., Haleon’s biggest market, coupled with broader economic uncertainty, the ongoing U.S. government shutdown and rising competition, had weighed on demand for the company’s seasonal and discretionary brands.
“EMEA & LatAm performed well, and we continued to grow market share in North America despite a challenging consumer environment,” CEO Brian McNamara said in a statement.
The Sensodyne toothpaste maker reported an organic revenue growth of 3.4% for the three months ended September 30, compared with analysts’ estimate of 3.3%, per a company-compiled poll.
Haleon, which also makes Advil painkillers and Centrum multi-vitamins, maintained its outlook for 2025.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Sumana Nandy)
Comments